1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
China National Accord Medicines Corporation Ltd Class A

China National Accord Medicines Corporation Ltd Class A

12.29
HKD
-0.06
(-0.49%)
13.97BMarket Cap
Apr 14Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
26.39
24.96
31.96
34.84
34.48
36.07
44.11
49.8
57.12
61.37
63.02
61.94
61.35
- -
Basic EPS, GAAP
0.65
0.68
0.78
1
0.88
1.01
1.06
1.17
1.12
1.24
1.34
0.54
0.95
- -
Free Cash Flow per Basic Share
0.39
-1.19
0.98
1.02
0.9
0.89
1.47
1.01
1.07
1.87
2.18
2.49
1.19
- -
Dividend per Share
0.27
0.22
0.19
0.18
0.21
0.23
0.41
0.46
0.51
0.48
0.47
0.5
0.32
0.62
Book Value per Share
2.79
4.7
7.26
8.34
7.86
9.71
10.79
11.66
12.48
13.48
14.56
14.77
15.56
15.78
Tangible Book Value per Share
2.49
4.48
6.03
7.21
6.89
8.75
9.64
8.75
9.6
10.64
11.75
12.82
13.88
14.11
Basic Weighted Avg Shares
803
960
1,183
1,184
1,197
1,195
1,197
1,198
1,197
1,197
1,198
1,201
1,197
756
Sales/Revenue/Turnover
21,199
23,954
37,819
41,248
41,263
43,122
52,787
59,649
68,358
73,443
75,477
74,378
73,416
- -
Operating Margin (%)
3.82
3.79
3.61
3.44
3.17
3.38
3.34
3.39
3.15
3.28
3.31
2.25
2.51
- -
Depreciation Expense
99
105
168
166
108
116
819
1,058
1,268
1,307
1,426
1,545
1,261
- -
Net Income, GAAP
520
652
928
1,187
1,058
1,211
1,268
1,402
1,336
1,487
1,599
642
1,136
- -
Effective Tax Rate (%)
18.95
19.23
20.62
19.9
21.1
19.69
20.05
20.21
22.65
23.34
20.81
58.82
25.23
- -
Profit Margin (%)
2.46
2.72
2.45
2.88
2.56
2.81
2.4
2.35
1.96
2.02
2.12
0.86
1.55
- -
Working Capital
979
3,304
4,730
5,553
6,191
9,738
9,932
9,005
9,469
10,681
12,032
12,774
14,091
14,485
LT Debt
- -
40
72
15
32
32
1,208
1,335
1,447
1,345
1,452
1,371
912
833
Total Equity
2,317
4,851
7,872
8,918
9,928
13,906
15,574
16,889
18,022
19,445
20,978
20,755
21,624
21,894
Return on Invested Capital (%)
11.84
10.9
12.13
12.28
10.35
9.43
8.17
8.66
6.98
7.74
7.9
0.9
4.36
- -
Return on Capital (%)
14.96
13.22
11.5
11.94
9.69
8.76
7.19
6.54
6.39
6.2
5.86
4.43
4.96
- -
Return on Common Equity (%)
25.89
18.62
15.31
15.01
11.85
11.52
10.34
10.44
9.26
9.58
9.54
3.66
6.26
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
3,343
3,233
2,519
LT Borrowings
- -
- -
- -
LT Finance Leases
912
862
833
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,196
1,196
1,196
Market Capitalization
13,045
13,091
12,088

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
40,196
40,308
39,489
Cash, Cash Equivalents & STI
7,802
5,179
5,933
Accounts Receivable, Net
21,538
23,899
22,771
Inventories
8,122
8,474
8,158
Total Current Liabilities
26,105
25,898
25,004
Payables & Accruals
- -
- -
- -
ST Debt
3,343
3,233
2,519
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.07%
5.12%
4.19%
Free Cash Flow
8.54%
11.83%
-52.45%
Net Income, GAAP
7.79%
6.22%
76.8%
Sales/Revenue/Turnover
7.11%
4.41%
-1.29%
Total Cash Common Dividend
8.88%
-5.12%
-36.02%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
19,090
18,695
18,680
17,912
74,378
2025
18,294
18,503
- -
18,291
73,416
2026
17,823
18,443
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.33
0.58
0.53
-0.69
0.54
2025
0.27
0.55
- -
0.29
0.95
2026
0.24
0.52
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
0.69
0.11
0.09
0.5
2025
0.04
0.41
- -
0.07
0.32
2026
0.03
0.64
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jin Xiong Li
Full Time Employees
28,336
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Yizhi Pharmaceutical Building Shenzhen GD China 518029
IPO Date
Aug 9, 1993
Website
szaccord.com.cn
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
China National Accord Medicines Corporation Ltd. (000028.SZ) engages in the wholesale distribution, retail, and related services for pharmaceutical and healthcare products primarily in China. The company offers drugs including proprietary Chinese medicines, chemical preparations, antibiotics, biochemical drugs, biological preparations, and diagnostic drugs; medical equipment and devices; health supplies, cosmetics, and daily necessities; cargo transportation, warehousing, loading and unloading, glass instruments, agent services, professional consulting, and house leasing; as well as import and export of therapeutic biological products, packaged foods, chemical products, house supplies, and self-operated technologies. It operates through pharmaceutical distribution focused on Guangdong and Guangxi regions with coverage of over 17,000 customers including hospitals, primary medical institutions, and retail terminals; pharmaceutical retail via its Guoda Drugstore subsidiary with approximately 7,660 stores across 20 provinces, municipalities, and autonomous regions; and industrial investments. As a subsidiary of Sinopharm Group Co., Ltd., it maintains a nationwide network with large-scale logistics centers in key cities, serving medical institutions, chain pharmacies, and consumers. Founded in 1993 and headquartered in Shenzhen, China, the company previously operated as Shenzhen Health Mineral Water Corp., Ltd. Recent developments include Guoda Drugstore's acquisitions of Chengda Fangyuan Pharmaceutical Group Co., Ltd. and Shanghai Dingqun Enterprise Management Consulting Co., Ltd. in 2020, adding over 1,500 stores and boosting retail scale; expansion of its own-brand portfolio with mid-to-high-end nutrient series through partnerships with Sinopharm affiliates like Sinopharm Medical Device and China TCM; and ongoing integration of wholesale and retail operations in 15 regions, alongside digital transformation for supply chain efficiency. In 2025, it reported earnings for periods ended March, June, and September, with dividends declared for 2024, reflecting continued focus on profitability amid market challenges.